Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Ventricular fibrillation and acute coronary syndrome [[electronic resource] /] / editor, Joyce E. Mandell
| Ventricular fibrillation and acute coronary syndrome [[electronic resource] /] / editor, Joyce E. Mandell |
| Pubbl/distr/stampa | Hauppauge, NY, : Nova Science, 2011 |
| Descrizione fisica | 1 online resource (248 p.) |
| Disciplina | 616.1/23 |
| Altri autori (Persone) | MandellJoyce E |
| Collana | Cardiology research and clinical developments |
| Soggetto topico |
Coronary heart disease
Ventricular fibrillation |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-61761-167-0 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
""VENTRICULAR FIBRILLATION AND ACUTE CORONARY SYNDROME""; ""VENTRICULAR FIBRILLATION AND ACUTE CORONARY SYNDROME""; ""CONTENTS ""; ""PREFACE""; ""CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME: CLINICAL IMPLICATIONS AND EMERGING THERAPIES ""; ""ABSTRACT ""; ""ABBREVIATIONS LIST ""; ""INTRODUCTION ""; ""RESISTANCE/VARIABLE RESPONSE TO CLOPIDOGREL. DOES IT EXIST? ""; ""MECHANISMS OF VARIABLE RESPONSE TO CLOPIDOGREL ""; ""Genetic Polymorphism ""; ""Drug-Drug Interactions ""; ""Statins ""; ""Proton Pump Inhibitors ""; ""Calcium-Channel Blockers ""
""IS IT POSSIBLE TO ACCURATELY ASSESS THE INHIBITORY EFFECT OF ANTIPLATELT DRUGS? """"CLINICAL IMPLICATIONS OF VARIABLE RESPONSE TO CLOPIDOGREL ""; ""Drug Eluting Stent""; ""WHAT TO DO WITH PATIENTS WITH REDUCED RESPONSE TO CLOPIDOGREL THERAPY? ""; ""Optimise Clopidogrel Response According to Platelet Function Tests ""; ""EMERGING THERAPIES ""; ""Prasugrel ""; ""Ticagrelor ""; ""Cangrelor ""; ""REFERENCES ""; ""PROTEOMICS OF ACUTE CORONARY SYNDROME ""; ""1. INTRODUCTION ""; ""2. PLASMA ""; ""3. BLOOD CELLS IN ACUTE CORONARY SYNDROME ""; ""3.1. Circulating Monocytes ""; ""3.2 Platelets "" ""3.3. Proteomics on Vascular Progenitors """"Endothelial Progenitor Cells (EPC) ""; ""4. TISSUE PROTEOMICS ""; ""Secretome ""; ""5. METABOLOMICS""; ""ABBREVIATIONS""; ""PROTEINS ABBREVIATIONS ""; ""REFERENCES ""; ""MAJOR BLEEDING IN ACUTE CORONARY SYNDROME: DEFINITIONS, MAGNITUDE OF THE PROBLEM, PREDICTORS, OUTCOMES, MANAGEMENT, AND PREVENTION ""; ""ABSTRACT ""; ""INTRODUCTION ""; ""DEFINITIONS OF MAJOR BLEEDING IN ACS ""; ""MAGNITUDE OF THE PROBLEM ""; ""PREDICTORS OF MAJOR BLEEDING ""; ""Age ""; ""Gender ""; ""History of Bleeding ""; ""Renal Impairment ""; ""Type of ACS "" ""Killip Class """"Diabetes Mellitus ""; ""Choice of Antiplatelet, Antithrombotic, and Fibrinolytic Agents""; ""Invasive Procedures ""; ""Blood Transfusion ""; ""Anemia ""; ""HOSPITAL OUTCOMES AND MAJOR BLEEDING ""; ""Mechanisms by Which Major Bleeding Affects Outcomes ""; ""Prevention and Management ""; ""CONCLUSION ""; ""REFERENCES""; ""NOVEL ANTIPLATELETS IN ACUTE CORONARY SYNDROMES ""; ""ABSTRACT ""; ""INTRODUCTION ""; ""ASPIRIN (ACETYLSALICYLIC ACID, ASA) ""; ""THIENOPYRIDINES ""; ""Ticlopidine ""; ""Clopidogrel ""; ""Prasugrel ""; ""Cangrelor (ARC-69931MX) ""; ""Ticagrelor (AZD6140) "" ""Elinogrel """"Bx667 ""; ""THROMBOXANE RECEPTOR ANTAGONISTS ""; ""Terutroban (S18886) ""; ""von Willebrand Factor Inhibitors ""; ""Ajw200 ""; ""Arc1779 ""; ""Alx-0081 ""; ""DIRECT THROMBIN INHIBITORS (PAR-1 INHIBITORS) ""; ""Sch 530348 ""; ""E5555 ""; ""CONCLUSION ""; ""REFERENCES ""; ""UNCONTROLLED IMMUNE RESPONSE IN ACUTE MYOCARDIAL INFARCTION ""; ""ABSTRACT""; ""INTRODUCTION ""; ""LEUKOCYTES ""; ""NEUTROPHILS ""; ""MONOCYTES ""; ""LYMPHOCYTES ""; ""Rationale and Clinical Evidence ""; ""Effector T-Cells ""; ""Regulatory T-Cells ""; ""The Inverted Pyramid Model "" ""THERAPEUTIC OPPORTUNITIES "" |
| Record Nr. | UNINA-9910461466803321 |
| Hauppauge, NY, : Nova Science, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Ventricular fibrillation and acute coronary syndrome [[electronic resource] /] / editor, Joyce E. Mandell
| Ventricular fibrillation and acute coronary syndrome [[electronic resource] /] / editor, Joyce E. Mandell |
| Pubbl/distr/stampa | Hauppauge, NY, : Nova Science, 2011 |
| Descrizione fisica | 1 online resource (248 p.) |
| Disciplina | 616.1/23 |
| Altri autori (Persone) | MandellJoyce E |
| Collana | Cardiology research and clinical developments |
| Soggetto topico |
Coronary heart disease
Ventricular fibrillation |
| ISBN | 1-61761-167-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
""VENTRICULAR FIBRILLATION AND ACUTE CORONARY SYNDROME""; ""VENTRICULAR FIBRILLATION AND ACUTE CORONARY SYNDROME""; ""CONTENTS ""; ""PREFACE""; ""CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME: CLINICAL IMPLICATIONS AND EMERGING THERAPIES ""; ""ABSTRACT ""; ""ABBREVIATIONS LIST ""; ""INTRODUCTION ""; ""RESISTANCE/VARIABLE RESPONSE TO CLOPIDOGREL. DOES IT EXIST? ""; ""MECHANISMS OF VARIABLE RESPONSE TO CLOPIDOGREL ""; ""Genetic Polymorphism ""; ""Drug-Drug Interactions ""; ""Statins ""; ""Proton Pump Inhibitors ""; ""Calcium-Channel Blockers ""
""IS IT POSSIBLE TO ACCURATELY ASSESS THE INHIBITORY EFFECT OF ANTIPLATELT DRUGS? """"CLINICAL IMPLICATIONS OF VARIABLE RESPONSE TO CLOPIDOGREL ""; ""Drug Eluting Stent""; ""WHAT TO DO WITH PATIENTS WITH REDUCED RESPONSE TO CLOPIDOGREL THERAPY? ""; ""Optimise Clopidogrel Response According to Platelet Function Tests ""; ""EMERGING THERAPIES ""; ""Prasugrel ""; ""Ticagrelor ""; ""Cangrelor ""; ""REFERENCES ""; ""PROTEOMICS OF ACUTE CORONARY SYNDROME ""; ""1. INTRODUCTION ""; ""2. PLASMA ""; ""3. BLOOD CELLS IN ACUTE CORONARY SYNDROME ""; ""3.1. Circulating Monocytes ""; ""3.2 Platelets "" ""3.3. Proteomics on Vascular Progenitors """"Endothelial Progenitor Cells (EPC) ""; ""4. TISSUE PROTEOMICS ""; ""Secretome ""; ""5. METABOLOMICS""; ""ABBREVIATIONS""; ""PROTEINS ABBREVIATIONS ""; ""REFERENCES ""; ""MAJOR BLEEDING IN ACUTE CORONARY SYNDROME: DEFINITIONS, MAGNITUDE OF THE PROBLEM, PREDICTORS, OUTCOMES, MANAGEMENT, AND PREVENTION ""; ""ABSTRACT ""; ""INTRODUCTION ""; ""DEFINITIONS OF MAJOR BLEEDING IN ACS ""; ""MAGNITUDE OF THE PROBLEM ""; ""PREDICTORS OF MAJOR BLEEDING ""; ""Age ""; ""Gender ""; ""History of Bleeding ""; ""Renal Impairment ""; ""Type of ACS "" ""Killip Class """"Diabetes Mellitus ""; ""Choice of Antiplatelet, Antithrombotic, and Fibrinolytic Agents""; ""Invasive Procedures ""; ""Blood Transfusion ""; ""Anemia ""; ""HOSPITAL OUTCOMES AND MAJOR BLEEDING ""; ""Mechanisms by Which Major Bleeding Affects Outcomes ""; ""Prevention and Management ""; ""CONCLUSION ""; ""REFERENCES""; ""NOVEL ANTIPLATELETS IN ACUTE CORONARY SYNDROMES ""; ""ABSTRACT ""; ""INTRODUCTION ""; ""ASPIRIN (ACETYLSALICYLIC ACID, ASA) ""; ""THIENOPYRIDINES ""; ""Ticlopidine ""; ""Clopidogrel ""; ""Prasugrel ""; ""Cangrelor (ARC-69931MX) ""; ""Ticagrelor (AZD6140) "" ""Elinogrel """"Bx667 ""; ""THROMBOXANE RECEPTOR ANTAGONISTS ""; ""Terutroban (S18886) ""; ""von Willebrand Factor Inhibitors ""; ""Ajw200 ""; ""Arc1779 ""; ""Alx-0081 ""; ""DIRECT THROMBIN INHIBITORS (PAR-1 INHIBITORS) ""; ""Sch 530348 ""; ""E5555 ""; ""CONCLUSION ""; ""REFERENCES ""; ""UNCONTROLLED IMMUNE RESPONSE IN ACUTE MYOCARDIAL INFARCTION ""; ""ABSTRACT""; ""INTRODUCTION ""; ""LEUKOCYTES ""; ""NEUTROPHILS ""; ""MONOCYTES ""; ""LYMPHOCYTES ""; ""Rationale and Clinical Evidence ""; ""Effector T-Cells ""; ""Regulatory T-Cells ""; ""The Inverted Pyramid Model "" ""THERAPEUTIC OPPORTUNITIES "" |
| Record Nr. | UNINA-9910790209203321 |
| Hauppauge, NY, : Nova Science, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||